Osimertinib plus Ramucirumab: The Best of Both Worlds?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33334907.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4026 and PMC identifier 7887048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced <i>EGFR</i> mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.<i>See related article by Yu et al., p. 992</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms